Rockwell Medical (RMTI) CEO awarded 352,000 performance-based stock units

Rhea-AI Filing Summary

Strobeck Mark reported acquisition or exercise transactions in this Form 4 filing.

Rockwell Medical, Inc. reported that President and CEO Mark Strobeck received a grant of 352,000 performance-based restricted stock units (PSUs) tied to the company’s common stock. The PSUs have a three-year term from the May 20, 2025 grant date and expire on May 20, 2028.

The units vest only if a stock price performance hurdle is achieved. During the three-year performance period, the average closing price over any 60 consecutive trading days must reach two times the base price. The base price for this award is $2.14, calculated from the average closing price over the ten trading days before the grant date.

Insights

Equity compensation analyst

CEO receives 352,000 performance-based PSUs with strict stock-price hurdle.

The filing shows Mark Strobeck, President and CEO of Rockwell Medical, was granted 352,000 performance-based restricted stock units. These are compensation-related awards, not open-market purchases or sales, and therefore carry limited traditional buy/sell signaling value.

The PSUs vest only if the stock achieves a demanding performance hurdle: during the three-year performance period, the average closing price over any 60 consecutive trading days must reach two times the base price. The base price is $2.14, based on the average closing price over the ten trading days before the grant date.

This structure links potential equity value for the CEO to sustained stock price appreciation over the three-year term ending on May 20, 2028. Actual value realized will depend on future share price performance and whether the performance hurdle is met.

Insider Trade Summary

1 transaction reported

Mixed 1 txn

Insider Strobeck Mark

Role President and CEO

Type	Security	Shares	Price	Value
Grant/Award	Performance-based restricted stock units	352,000	$0.00	--

Holdings After Transaction: Performance-based restricted stock units — 352,000 shares (Direct)

Footnotes (1)

1. [object Object]

Key Figures

PSU grant size: 352,000 units Underlying shares: 352,000 shares Base price: $2.14 +2 more

5 metrics

PSU grant size 352,000 units Performance-based restricted stock units granted to CEO on May 20, 2025

Underlying shares 352,000 shares Common stock underlying the granted PSUs

Base price $2.14 Average closing price over ten trading days before the grant date

Performance period length 3 years Term and performance period from grant date to third anniversary

Expiration date May 20, 2028 Date when any unvested PSUs are cancelled

Key Terms

performance-based restricted stock units, PSU, performance hurdle, base price

4 terms

performance-based restricted stock units financial

"These are performance-based restricted stock units ("PSU") with terms as follows."

Performance-based restricted stock units are a type of employee equity award that converts into company shares only if predefined financial or operational targets are met over a set period. Think of it like a bonus check that becomes stock only when specific goals are hit; it ties pay to results, aligning managers’ incentives with shareholders. Investors care because these awards affect future share count, executive incentives, and signal how management’s success will be measured and rewarded.

PSU financial

"These are performance-based restricted stock units ("PSU") with terms as follows."

A PSU is a company where the government owns a controlling stake and often plays a direct role in its management and strategy. Think of it like a business that operates with public oversight, similar to a town-run utility versus a private neighborhood service. Investors watch PSUs differently because government involvement can affect profits, dividend policies, regulatory treatment and stability, so these stocks may behave more like policy instruments than pure market-driven enterprises.

performance hurdle financial

"PSUs will vest on or after the first anniversary of the grant date only if the stock price meets the performance hurdle."

base price financial

"The base price was calculated as the average closing price over the ten trading days ending on the trading day prior to the grant date and is $2.14 for this award."

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Form 4 Insider Transactions: What Each Field Means →

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Strobeck Mark

(Last) (First) (Middle)

C/O ROCKWELL MEDICAL, INC.

30142 WIXOM ROAD

(Street)

WIXOM MICHIGAN 48393

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
ROCKWELL MEDICAL, INC. [ RMTI ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	President and CEO

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
05/20/2025

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)
05/21/2025

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Performance-based restricted stock units	(1)	05/20/2025		A(1)		352,000		(1)	05/20/2028	Common Stock	352,000	$0	352,000	D

Explanation of Responses:

1. These are performance-based restricted stock units ("PSU") with terms as follows. The term of each PSU award runs from the grant date through the third anniversary of the grant date. Any unvested PSUs remaining after the third anniversary will be cancelled. The performance period for the award is the same three-year period. PSUs will vest on or after the first anniversary of the grant date only if the stock price meets the performance hurdle. The performance hurdle is met if the average closing price of the Company's common stock over any 60 consecutive trading days during the performance period equals two times the base price. The base price was calculated as the average closing price over the ten trading days ending on the trading day prior to the grant date and is $2.14 for this award.

Remarks:

This award was inadvertently omitted from the original Form 4.

	/s/ Megan Timmins, Attorney-in-Fact for Mark Strobeck	04/17/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

FAQ

What did Rockwell Medical (RMTI) disclose about CEO Mark Strobeck’s new equity grant?

Rockwell Medical disclosed that CEO Mark Strobeck received 352,000 performance-based restricted stock units. These PSUs are linked to the company’s common stock and serve as incentive compensation, vesting only if specific multi-year stock price performance conditions are achieved over the three-year performance period.

How many performance-based restricted stock units did RMTI grant to its CEO?

Rockwell Medical granted its CEO 352,000 performance-based restricted stock units. Each unit is tied to one share of common stock. The award is structured to vest only if a stock price performance hurdle is met during a defined three-year period, otherwise unvested units are cancelled.

What is the performance hurdle for Rockwell Medical (RMTI) CEO’s PSU award?

The PSUs vest only if the average closing price of Rockwell Medical’s common stock over any 60 consecutive trading days equals two times the base price. This performance hurdle must be achieved during the three-year performance period that begins on the grant date of the award.

What is the base price used in Rockwell Medical (RMTI) CEO’s PSU calculation?

The base price for the CEO’s PSU award is $2.14. It was calculated as the average closing price of Rockwell Medical’s common stock over the ten trading days ending on the trading day before the grant date, and is used to define the stock price hurdle.

When do Rockwell Medical (RMTI) CEO’s performance-based RSUs vest or expire?

The PSUs can vest on or after the first anniversary of the grant date if the stock meets the performance hurdle. The term runs through the third anniversary of the grant date, and any PSUs still unvested after that third anniversary are cancelled and no longer eligible to vest.

Are Rockwell Medical (RMTI) CEO’s new PSUs an open-market stock purchase?

No, the filing describes a grant of performance-based restricted stock units as compensation. The transaction code indicates a grant or award acquisition, not an open-market buy or sell. Any future value from these PSUs depends on stock performance and vesting conditions being satisfied.